Review: COVID-19-associated coagulopathy and antithrombotic agents – In non-critically ill hospitalized patients, therapeutic dose anticoagulation may improve clinical outcomes. In critically ill patients, this same treatment does not improve outcomes, and prophylactic dose anticoagulation is recommended

COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year – The Lancet Haematology

Related: Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials AND RCT: Intermediate-dose enoxaparin (1 mg/kg/d) not better than standard-dose prophylactic anticoagulation in patients with Covid-19 admitted to the intensive care unit

Commentary on Twitter

???State of the Art Review Article @TheLancetHaem by @MiddeldorpS
COVID-19-associated coagulopathy
Excellent explanation for the pathophysiology and great summary for the major RCTs and clinical guidelines https://t.co/NxP06KP2Hm pic.twitter.com/qHzyDsUZpt

— Antibiotic Steward??Bassam Ghanem (@ABsteward) April 28, 2021